Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment.
about
Unexpected expression pattern for glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) in mouse tissues revealed by positron emission tomography scanning.A modular IgG-scFv bispecific antibody topology.Recombinant carcinoembryonic antigen as a reporter gene for molecular imagingEngineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies).Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins.Evaluation of two internalizing carcinoembryonic antigen reporter genes for molecular imagingThe potential and hurdles of targeted alpha therapy - clinical trials and beyond.Cancer radioimmunotherapy.Improved modeling of in vivo kinetics of slowly diffusing radiotracers for tumor imaging.A fully human scFv phage display library for rapid antibody fragment reformattingAdvances in immuno-positron emission tomography: antibodies for molecular imaging in oncologyPositron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments.A self-assembling short oligonucleotide duplex suitable for pretargetingIn vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.Impact of expression system on the function of the C6.5 diabody PET radiotracerSite-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumorsChapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.Using antibodies to target cancer therapeutics.Monoclonal antibody treatments for rheumatoid arthritis.Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.Deglycosylation of mAb by EndoS for improved molecular imaging.Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragmentAn affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.Studies towards the improvement of an anti-cocaine monoclonal antibody for treatment of acute overdose.Novel human single chain antibody fragments that are rapidly internalizing effectively target epithelioid and sarcomatoid mesotheliomasSaturation mutagenesis on Tyr205 of the cyclic dipeptide C2-prenyltransferase FtmPT1 results in mutants with strongly increased C3-prenylating activity.
P2860
Q30497599-7B3C0E43-1410-4898-A76E-93698FCEE68DQ33519465-6EE86C6A-E419-4F76-8423-1B17D1D1B35CQ33579549-DC91FAD0-39C6-4172-ABF0-0689BA47AD5EQ33661948-C862E026-292B-4826-BA73-E85BEB6265C8Q33738721-6BA4CA12-FFE3-4AD5-BA2B-E0936B93729AQ33781006-23D54344-E376-40EE-94BC-718138053A86Q34109974-CB87AE59-7E16-4C9E-AD6B-DA68674A6F32Q34354220-9AFD9641-BEC1-410E-B887-B78BC1CAEFF4Q34399879-9CE99B7F-C759-4674-B31E-9D02C6703494Q35070045-F0585998-C817-4FC6-B2AC-C371CF912C82Q35101117-C3036444-E297-45ED-A592-4A1163D07D1CQ35635839-F6B7726A-AF4E-4664-BDB4-7BE433BBDCBDQ36339722-B3233350-8974-4C97-9267-F9A87A366EB5Q36557471-F41D45D7-1499-418C-8C7E-C3C7DB00A817Q37044940-F854603B-6612-42A3-967E-C7E90B3F6627Q37129823-E5EF44BB-54E8-41D2-8F7E-516854C0233FQ37142836-EA3E7CEE-13F4-41C5-9842-CAB720032704Q37158166-E17F436B-D9EC-47A3-85A3-C07F2BB5DB6FQ37289040-F8FF7D75-5D8E-44AF-BB0A-5D1E2C086CEFQ37597698-E89DD7A6-CC25-42EA-B219-C456605F2C9BQ38014920-3CDA5217-DF37-4CE6-8A15-B1DA6F37DB01Q38116065-351AD44E-C513-4B40-B53C-1CB3050E6DA5Q38831148-7F4AD07F-2515-40CD-BABB-3C4379610EC7Q38964828-C8F4BA74-1B82-4FA3-91F2-B5456AD9B1FFQ39417962-F6267DAC-0CE7-4732-8294-D88356F1EB37Q39720680-4C9EDE91-2B73-4256-8A1C-F32B87E0189AQ40976323-A74D9EFC-0CBE-4192-B338-C767F53376C7Q42387566-85BC8DE1-145E-4DD4-922C-5B7A3EC9C632Q42711592-B52B2A94-CE6F-41CD-A839-9F29620DDB7BQ51699488-3885BE89-1C54-49D5-BAEB-DCBFC4A41074
P2860
Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Tunable pharmacokinetics: modi ...... utagenesis of the Fc fragment.
@en
Tunable pharmacokinetics: modi ...... utagenesis of the Fc fragment.
@nl
type
label
Tunable pharmacokinetics: modi ...... utagenesis of the Fc fragment.
@en
Tunable pharmacokinetics: modi ...... utagenesis of the Fc fragment.
@nl
prefLabel
Tunable pharmacokinetics: modi ...... utagenesis of the Fc fragment.
@en
Tunable pharmacokinetics: modi ...... utagenesis of the Fc fragment.
@nl
P2093
P2860
P356
P1433
P1476
Tunable pharmacokinetics: modi ...... utagenesis of the Fc fragment.
@en
P2093
Tove Olafsen
Vania E Kenanova
P2860
P2888
P304
P356
10.1038/NPROT.2006.322
P577
2006-01-01T00:00:00Z